Back to search results

Understanding Outcomes for Adolescent and Young Adult Lymphoma Survivors

This study is looking at how social and genetic factors affect the health and survival of young people (ages 15-39 at diagnosis) who have survived Hodgkin lymphoma or non-Hodgkin lymphoma. Researchers want to understand why some adolescent and young adult (AYA) cancer survivors experience more health problems or die sooner after treatment compared to others. You would provide blood samples and complete questionnaires about your health and quality of life. The study aims to identify factors that increase the risk of getting sick or dying after cancer treatment, ultimately helping doctors better support AYA cancer survivors. Success will be measured by how long participants live without their cancer returning (disease-free survival, DFS) and overall survival (OS), as well as by tracking other health issues (comorbidities) for up to two years.

Study design
This is an observational study planning to enroll 2000 participants. It is not testing a new treatment but rather observing health outcomes.
What's involved
You would complete questionnaires and provide blood samples at the start of the study, and then again at 6, 12, 18, and 24 months.
Compensation
Not stated in the trial record.
Follow-up
Your health will be tracked for up to two years to measure disease-free survival, overall survival, and comorbidities.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06002828

Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors

Recruiting
Not specifiedAges 18+Observational
ECOG-ACRIN Cancer Research Group
~2,000 participants
Updated 2026-06-18 on ClinicalTrials.gov
What's tested:Biospecimen CollectionQuality-of-Life AssessmentQuestionnaire Administration

At a glance

Recruiting sites
405 of 428 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Disease free survival (DFS)
Measured over Time interval after primary treatment for a cancer ends that the patient survives without any signs or symptoms of thatcancer, assessed up to 2 years
+2 more outcomes measured

Conditions

Hodgkin Lymphoma
Non-Hodgkin Lymphoma

Explore related trials

Hodgkin's GranulomaNon-Hodgkin Lymphoma

Where it's being run

428 sites across 31 states
Michigan54
Illinois50
Wisconsin47
Nevada43
Minnesota41
Missouri27
Washington21
Colorado19

Study leadership

  • Bradley J Zebrack · PRINCIPAL_INVESTIGATOR · ECOG-ACRIN Cancer Research Group

Who to contact

Site Public Contact
[email protected]
907-212-6871
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patient must be \>= 18 years of age at the time of registration
Patient must have been between the ages of 15-39 at the time of their first primary cancer diagnosis of Hodgkin lymphoma or non-Hodgkin lymphoma (NHL)
Patient must have completed therapy (with a complete response, per clinician determination) at the time of registration
Patients last date of prior systemic therapy for first primary diagnosis for Hodgkin lymphoma or non-Hodgkin lymphoma must have been within one year prior to registration
NOTE: Systemic therapy refers to all anti-cancer therapy, including but not limited to chemotherapy, intravenous (IV) or oral targeted medications, or radiation, and administered via a clinical trial or standard approach
Patient must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-3
Patient must be English speaking in order to be able to complete the required QOL forms on this study
NOTE: Sites cannot translate the associated QOL forms
Patient must not be receiving active therapy for Hodgkin lymphoma or non-Hodgkin lymphoma
Patient must have internet access through computer, tablet, or smartphone
Patient must have email address
Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible

What this trial measures

  • Disease free survival (DFS)Time interval after primary treatment for a cancer ends that the patient survives without any signs or symptoms of thatcancer, assessed up to 2 years

    A gated hypothesis testing procedure will be used to ensure control of the family-wise error rate at 0.05 (two-sided). Cox regression will be used to assess the association of the social-environmental risk factors with the hazard of DFS.

  • Overall survival (OS)From participant registration to the date of death or censored at the date of data collection, assessed up to 2 years

    A gated hypothesis testing procedure will be used to ensure control of the familywise error rate at 0.05 (two- sided). OS will be tested only if statistical significance is achieved for DFS. Cox regression will be used to assess the association of the social-environmental risk factors with the hazard of OS.

  • Comorbidities (including symptoms, late effects)Up to 2 years

    Will be assessed using Charlson Comorbidity Index (Patient version) National Cancer Institute Common Toxicity Criteria for Adverse Events.